HemaCare Corporation has expanded its global capabilities through a strategic distribution agreement in Israel with Almog Diagnostic. This partnership ensures researchers in the Israeli life sciences community can access HemaCare’s human healthy and disease state hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local regional support. HemaCare distribution agreements enable partners to actively provide support to customers. Researchers will be able to obtain human biological material collected from HemaCare’s FDA-registered donor collection centers, as well as fresh and frozen hematopoietic cell products derived from its cell isolation laboratory in California, while receiving customer service and technical support in their native language through specially trained representatives locally in their region. To ensure best in class service and support, HemaCare provides ongoing technical training and marketing support to its global partners.